1. Home
  2. ANIX vs PFX Comparison

ANIX vs PFX Comparison

Compare ANIX & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

N/A

Current Price

$3.00

Market Cap

103.9M

Sector

Health Care

ML Signal

N/A

PFX

PhenixFIN Corporation

N/A

Current Price

$43.50

Market Cap

86.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ANIX
PFX
Founded
1982
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
103.9M
86.7M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
ANIX
PFX
Price
$3.00
$43.50
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $9.67
N/A
AVG Volume (30 Days)
★ 203.7K
942.0
Earning Date
09-09-2026
12-11-2026
Dividend Yield
N/A
★ 3.27%
EPS Growth
★ 12.82
N/A
EPS
N/A
★ 0.30
Revenue
★ $210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$145.67
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$38.30
52 Week High
$5.46
$56.48

Technical Indicators

Market Signals
Indicator
ANIX
PFX
Relative Strength Index (RSI) 51.58 49.65
Support Level $2.77 $41.86
Resistance Level $3.09 $44.56
Average True Range (ATR) 0.18 0.17
MACD 0.05 0.06
Stochastic Oscillator 47.65 83.15

Price Performance

Historical Comparison
ANIX
PFX

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: